Rotavirus vaccine benefits outweigh viral contamination risks, US experts say
This article was originally published in Scrip
Executive Summary
The benefits of two US FDA-licensed rotavirus vaccines, GlaxoSmithKline's Rotarix and Merck & Co's Rotateq, outweigh the theoretical risks posed by the presence of porcine circovirus (PCV) contamination in the products, the agency's vaccines advisory panel has said.